Edwards Lifesciences (EW) Intrinsic Value Calculator

Updated: Nov 16, 2026

Edwards Lifesciences (EW) trades at $106.66 against a base-case intrinsic value of $77.81 — roughly a 37% premium to fair value. The model starts from $3.39 in expected earnings per share, grows it at 12.4% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 25.0x exit multiple, and discounts the result back at 10% per year. At today's price, the market is pricing in either faster earnings growth or a higher exit multiple than EW's own history supports. Use the sliders below to see what growth assumptions would be needed to justify the current price.

Overvalued by 27.0%
Current Price
$106.66
Intrinsic Value
$77.81
Implied Upside: -27.0%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate 12.4%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 25.0x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$77.81
--
Tradestie Long-Horizon Cycle Intelligence (2008–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (18-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Orthopedic, Prosthetic & Surgical Appliances & Supplies • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Orthopedic, Prosthetic & Surgical Appliances & Supplies, only 23.3% of peer companies at >$5B revenue scale (180 historical 5-year windows; industry median CAGR: 4.1%/yr) sustained ≥8%/yr 5-year compound revenue growth (broad >$5B equity base rate: 25.6%).

≥5%/yr (5Y)
43.3%
All >$5B: 42.8%
≥10%/yr (5Y)
13.9%
All >$5B: 17.5%
≥15%/yr (5Y)
4.4%
All >$5B: 8.0%
≥20%/yr (5Y)
1.7%
All >$5B: 4.1%
≥25%/yr (5Y)
0.6%
All >$5B: 2.5%
≥30%/yr (5Y)
0.0%
All >$5B: 1.4%
18-Yr Revenue Scale
$1.24B → $6.07B
17Y CAGR: +9.8%/yr • 5Y: +6.7%
2008–2009 Cycle Trough Floor
Post-2009 Series
Tracked from FY2008
2022 Rate-Shock Floor
26.1% Op Margin
FY2023 Rev: $5.01B (+12.2% YoY)
Latest vs Cycle Median Margin
20.8% vs 26.1% med
Fortress Through-Cycle Margin (>15% Floor)
Multi-Cycle Revenue & Operating Margin Trajectory (2008–2025) Expansion 2008–09 / 2022 Macro Stress
'08
'09
'10
'11
'12
'13
'14
'15
25%
'16
32%
'17
20%
'18
26%
'19
21%
'20
32%
'21
34%
'22
26%
'23
25%
'24
21%
'25
Inspect All 18 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $6.07B +11.5% $1.26B 20.8% Standard
FY2024 (2024-12) $5.44B +8.6% $1.38B 25.3% Standard
FY2023 (2023-12) $5.01B +12.2% $1.31B 26.1% 2022–23 Shock Floor
FY2022 (2022-12) $4.46B -14.7% $1.50B 33.6% 2022 Rate Shock
FY2021 (2021-12) $5.23B +19.3% $1.69B 32.3% Standard
FY2020 (2020-12) $4.39B +0.9% $898M 20.5% Standard
FY2019 (2019-12) $4.35B +16.8% $1.15B 26.4% Standard
FY2018 (2018-12) $3.72B +8.4% $748M 20.1% Standard
FY2017 (2017-12) $3.44B +15.9% $1.09B 31.7% Standard
FY2016 (2016-12) $2.96B +18.8% $751M 25.3% Standard
FY2015 (2015-12) $2.49B +7.4% N/A — Standard
FY2014 (2014-12) $2.32B +13.6% N/A — Standard
FY2013 (2013-12) $2.05B +7.7% N/A — Standard
FY2012 (2012-12) $1.90B +13.2% N/A — Standard
FY2011 (2011-12) $1.68B +16.0% N/A — Standard
FY2010 (2010-12) $1.45B +9.5% N/A — Standard
FY2009 (2009-12) $1.32B +6.8% N/A — 2008–09 Cycle Stress
FY2008 (2008-12) $1.24B — N/A — 2008–09 Cycle Stress

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

Model Inputs
Base EPS $3.39
Current Price $106.66
Historical PE 25.0x
Analyst Growth Est. 12.4%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).